Passage of House bill prompts questions

The passage of the US House of Representatives healthcare bill on Saturday is already raising questions about how specific sectors, from medical device makers to needle clinics for drug users, will fare, as a result.

The passage of the US House of Representatives healthcare bill on Saturday is already raising questions about how specific sectors, ranging from medical device makers to needle clinics for drug users, will fare.

Business groups like the Business Roundtable and the National Federation of Independent Business have criticized the bill and how it will affect employers, while biotechnology trade groups are preparing for new generic provisions that will provide protection for 12 years.

Looking ahead, Pfizer and WellPoint are focusing their efforts on the Senate to soften the effect of the bill on their businesses.

Following the passage of the bill, President Barack Obama sent an e-mail to the Organizing for America audience, encouraging continued activism and donation. Republican leaders have focused their message on the Democrats' decision to push for an agenda for reform over the needs of voters.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.